N/A N=25

Perioperative Hypogonadism in Men Undergoing Radical Cystoprostatectomy for Bladder Cancer

Bladder Cancer · Low Testosterone Levels

Bottom Line

View on ClinicalTrials.gov: NCT03063125 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

May 2021

Primary outcome: Primary: Number of Hypogonadism in Participants Based on Serum Testosterone 90 Days Post Radical — 6 participants

Study Design & Population

Study type: Observational
Phase: N/A
Interventions: —
Age: Adult, Older Adult · 18+ yrs
Sex: Male
Sponsor: University of Kansas Medical Center
Primary completion: Apr 2018

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Hypogonadism in Participants Based on Serum Testosterone 90 Days Post Radical	6	—
SECONDARY The Number of Hypogonadism in Participants Based on Serum Testosterone 30 Days Post Radical Cystectomy	8	—
SECONDARY The Number of Hypogonadism in Participants Based on Serum Testosterone Immediately Post Surgery Days Post Radical Cystectomy	19	—
SECONDARY The Number of Hypogonadism in Participants Based on Serum Testosterone at Baseline Days Post Radical Cystectomy	12	—

Summary

The purpose of this study is to examine the relationship between testosterone level changes around the time of radical cystectomy.

Eligibility Criteria

Inclusion Criteria

Diagnosis of bladder cancer
Scheduled to undergo radical cystectomy

Exclusion Criteria

Evidence of advanced metastatic disease,
Undergoing cystectomy for non-bladder primary malignancy or bladder cancer type other than urothelial cell
History of breast or prostate cancer
Polycythemia, cardiovascular thromboembolism, untreated obstructive sleep apnea, uncontrolled heart failure, or acute coronary event in the past six months

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03063125). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.